The sleeve versus bypass trial is a randomized multi-centre trial, in which two bariatric medical centres are participating. In order to determine the area of indication for the LSG in the field of bariatric surgery patients in this study are also stratified at randomisation for sex, T2 DM and a BMI below or above 50В kg/m 2. QOL, resolution of obesity-related-comorbidity, complications and revision bariatric surgery due to insufficient weight loss or GERD). The primary aim of this multicentre study is to compare LSG with standard LRYGB in terms of percentage excess BMI loss (%EBMIL) as well as in secondary outcomes (e.g. However, concerns remain that the sleeve will lose its effect in time, resulting in a decline of weight loss and reappearance of obesity-related comorbidity. In these studies the percentage excess BMI loss (%EBMIL) appeared to be equal for both techniques.

So far results of RCTs with small number of patients and short-term outcome have been published only. Quality of life (QOL) appears to be similar or even better after LSG compared to LRYGB due to the mentioned advantages. The most profound possible disadvantage is that LSG is irreversible. LSG has some potential advantages it is a faster and safe procedure where the duodenum is still accessible for endoscopy, there is less dumping due to the pylorus and second stage procedures (LRYGB or BPD-duodenal switch) are standard procedures. LSG is becoming more popular and is performed in 28В % of bariatric procedures worldwide in 2011. As weight loss results following LSG were excellent, necessitating a second stage procedure in only a quarter of the patients, LSG is currently used as a single stage procedure in morbidly obese patients. Laparoscopic sleeve gastrectomy (LSG) is a relatively new procedure which started as a first stage procedure before a duodenal switch (DS) in super obese patients to reduce treatment related mortality. There are advantages of LRYGB being fully reversible, well documented in terms of early morbidity and long term results known for more than 50В years and often regarded as the gold standard in bariatric and metabolic surgery. Laparoscopic Roux-en-Y gastric bypass (LRYGB) is considered the best surgical option for morbid obesity and as a result is still one of the most frequently performed bariatric procedure worldwide. Besides weight loss, it also has profound effects on obesity-related comorbidities, such as T2DM, hypertension and sleep apnoea. Morbid obesity is defined as having a body mass index (BMI)вЂ‰в‰ҐвЂ‰40 or BMI 35В kg/m 2 combined with at least one comorbid condition, such as type 2 diabetes (T2 DM), hypertension, dyslipidaemia, or sleep apnoea.Д«ariatric surgery is considered the best treatment to realize long-term sufficient weight loss in morbidly obese patients. When patients become morbidly obese, health risks increase rapidly. It induces health risks, diminishes quality of life, psychosocial problems and increases public costs. If weight loss is comparable, obesity-related comorbidity and QOL after bariatric procedures should be taken into account when deciding on which surgical technique is to be preferred for certain subgroups in the future. Long-term %EBMIL between the two treatment strategies used to be in favour of LRYGB, but more recent results throughout the world show similar %EBMIL in both techniques. Secondary endpoints are resolution of obesity related comorbidity, complications, revision bariatric surgery and quality of life (QOL) defined in various questionnaires. The primary endpoint is the 5-year weight loss (%EBMIL) of LSG and LRYGB. Only surgeons experienced in both operation techniques will participate in the Sleeve Bypass trial. A total number of 620 patients will be enrolled and equally (1:1) randomized to both treatment arms. At randomization patients are stratified for centre, sex, T2 DM and BMIвЂ‰в‰ҐвЂ‰50В kg/m 2. Patients with a body mass index (BMI)вЂ‰в‰ҐвЂ‰40В kg/m 2 or BMI 35В kg/m 2 with obesity related comorbidity (T2 DM, sleep apnoea, hypertension) are eligible for randomization. The Sleeve Bypass Trial is a randomized multicentre clinical trial: patients eligible for bariatric surgery are randomized to either LSG or LRYGB. Our hypothesis is that LSG has a similar percentage excess BMI loss (%EBMIL) after 5В years compared to LRYGB. The aim of this study is to evaluate the efficiency of both techniques. Laparoscopic Sleeve Gastrectomy (LSG) is a new promising bariatric procedure which has the advantage of maintaining an intact gastrointestinal tract. Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) is the gold standard surgical technique. Bariatric surgery is the only effective therapy to induce sufficient long-term weight loss for morbidly obese patients. Obesity is an increasing disease worldwide.

Jaikoz trial bypass